GlassScriptPhysician profile
Louis A Akra
NPI 1801827175
$2,109.40
in general payments reported to CMS, 2019-2025
29 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $150 · 2021: $283 · 2022: $459 · 2023: $312 · 2024: $292 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $914.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $866.57 | 2019-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $151.88 | 2021-2023 | |
| Lilly USA, LLC | $140.30 | 2022-2025 | Mounjaro, Kisunla, Amyvid |
| Eisai INC. | $104.74 | 2019-2024 | |
| Idorsia Pharmaceuticals US INC | $103.55 | 2022-2024 | Quviviq |
| Pfizer INC. | $86.23 | 2024-2025 | |
| Novo Nordisk INC | $59.62 | 2021-2025 | Ozempic |
| Arbor Pharmaceuticals, INC. | $55.80 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $55.16 | 2019-2023 | Fasenra |
| Glaxosmithkline, LLC. | $51.39 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $36.58 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.08 | 2021-2022 | |
| Astellas Pharma US INC | $32.67 | 2023-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.89 | 2020-2024 | |
| Radius Health, INC. | $28.87 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $27.35 | 2020-2025 | Zoryve |
| Medtronic USA, INC. | $25.56 | 2019 | |
| Merck Sharp & Dohme LLC | $23.61 | 2024 | Dificid |
| Corium, LLC | $21.64 | 2022 | |
| Ibsa Pharma INC. | $20.39 | 2019 | |
| Metuchen Pharmaceuticals | $19.77 | 2019 | |
| Insmed, INC. | $19.38 | 2025 | Arikayce |
| Exact Sciences Corporation | $18.43 | 2025 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $17.79 | 2019 | |
| Biogen, INC. | $17.40 | 2021 | |
| Supernus Pharmaceuticals, INC. | $16.02 | 2022 | |
| Endo Pharmaceuticals INC. | $15.16 | 2019 | |
| Allergan, INC. | $14.88 | 2020 | |
| Paratek Pharmaceuticals, INC. | $12.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Akra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.